DOP2011000041A - Tratamiento de enfermedad autoinmunitaria e inflamatoria - Google Patents

Tratamiento de enfermedad autoinmunitaria e inflamatoria

Info

Publication number
DOP2011000041A
DOP2011000041A DO2011000041A DO2011000041A DOP2011000041A DO P2011000041 A DOP2011000041 A DO P2011000041A DO 2011000041 A DO2011000041 A DO 2011000041A DO 2011000041 A DO2011000041 A DO 2011000041A DO P2011000041 A DOP2011000041 A DO P2011000041A
Authority
DO
Dominican Republic
Prior art keywords
autoimmunity
treatment
inflammatory disease
biological activity
multiple sclerosis
Prior art date
Application number
DO2011000041A
Other languages
English (en)
Inventor
Stewart Leung
Lixin Li
Xuebin Liu
Hongtao Lu
Ping Tsui
Jingwu Zang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DOP2011000041A publication Critical patent/DOP2011000041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona nuevos procedimientos de tratamiento de la esclerosis multiple y otras enfermedades autoinmunitarias o trastornos inflamatorios, y antagonistas, que incluyen proteinas de union aisladas para su uso en los nuevos procedimientos. Se proporciona un procedimiento de tratamiento de la esclerosis multiple que comprende la neutralizacion de la actividad biologica de la IL-7 mediante la union a CD127 o a IL-7. Las proteinas de union aisladas tambien pueden neutralizar la actividad biologica de la TSLP.
DO2011000041A 2008-08-08 2011-02-02 Tratamiento de enfermedad autoinmunitaria e inflamatoria DOP2011000041A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8729408P 2008-08-08 2008-08-08
US16980109P 2009-04-16 2009-04-16
US21862709P 2009-06-19 2009-06-19

Publications (1)

Publication Number Publication Date
DOP2011000041A true DOP2011000041A (es) 2011-02-28

Family

ID=41382165

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000041A DOP2011000041A (es) 2008-08-08 2011-02-02 Tratamiento de enfermedad autoinmunitaria e inflamatoria

Country Status (23)

Country Link
US (2) US20110287000A1 (es)
EP (1) EP2318442A1 (es)
JP (1) JP2011530533A (es)
KR (1) KR20110044777A (es)
CN (1) CN102177179A (es)
AR (1) AR072985A1 (es)
AU (1) AU2009279471A1 (es)
BR (1) BRPI0916945A2 (es)
CA (1) CA2733432A1 (es)
CL (1) CL2011000269A1 (es)
CO (1) CO6341640A2 (es)
CR (1) CR20110118A (es)
DO (1) DOP2011000041A (es)
EA (1) EA201100150A1 (es)
IL (1) IL211034A0 (es)
MA (1) MA32621B1 (es)
MX (1) MX2011001477A (es)
NZ (1) NZ590994A (es)
PE (1) PE20110382A1 (es)
TW (1) TW201018482A (es)
UY (1) UY32038A (es)
WO (1) WO2010017468A1 (es)
ZA (1) ZA201100974B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8171134B2 (en) * 2009-03-18 2012-05-01 At&T Intellectual Property I, L.P. Methods and apparatus to characterize and predict network health status
KR20130028055A (ko) 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
US20130046015A1 (en) * 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
AU2014201648B2 (en) * 2010-02-24 2016-05-12 Rinat Neuroscience Corp. Antagonist anti-il-7 receptor antibodies and methods
CA2801509A1 (en) 2010-06-02 2011-12-08 Dainippon Sumitomo Pharma Co., Ltd. Treatment drug for autoimmune diseases and allergic diseases
WO2012021165A2 (en) * 2010-08-10 2012-02-16 The Scripps Research Institute Methods and compositions for treating disorders associated with hyperactive immune system
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
GB2535937B (en) * 2014-04-29 2017-05-31 Bio-Cancer Treat Int Ltd Arginase I for treating rheumatoid arthritis
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
JP2017534577A (ja) * 2014-09-15 2017-11-24 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法
EP3207061A1 (en) 2014-10-18 2017-08-23 Pfizer Inc Anti-il-7r antibody compositions
WO2016142426A1 (en) * 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
AU2016335750B2 (en) 2015-10-07 2023-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
BR112018067479A2 (pt) 2016-02-29 2019-01-15 Ose Immunotherapeutics anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmo
RU2769352C2 (ru) 2016-12-09 2022-03-30 Осе Иммьюнотерапьютикс Антитела и полипептиды, направленные против cd127
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
BR112021014106A2 (pt) * 2019-01-22 2021-10-13 Bristol-Myers Squibb Company Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
CN117343173A (zh) * 2019-03-07 2024-01-05 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN115279404A (zh) 2020-02-13 2022-11-01 安进公司 人抗tslp抗体的配制品及治疗炎性疾病的方法
US20230073888A1 (en) 2020-02-13 2023-03-09 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
JP2023513833A (ja) 2020-02-18 2023-04-03 アムジェン インコーポレイテッド ヒト抗ｔｓｌｐ抗体の製剤及びそれを使用する方法
MX2023006294A (es) 2020-12-02 2023-06-13 Glaxosmithkline Ip Dev Ltd Proteinas de union a il-7 y su uso en tratamientos medicos.
WO2023227641A1 (en) 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194375A (en) * 1989-06-15 1993-03-16 Immunex Corporation Dna encoding interleukin-7 receptors and methods of use
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994028160A1 (fr) * 1993-06-01 1994-12-08 Toray Industries, Inc. Anticorps monoclonal, procede de production, et utilisation
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
WO2005123774A2 (en) * 2004-06-15 2005-12-29 Erol Fikrig Antibodies to west nile virus polypeptides
WO2006052660A2 (en) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
PE20061391A1 (es) * 2005-02-14 2007-01-09 Wyeth Corp Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f
CA2513350A1 (en) * 2005-03-02 2006-09-02 Sydney West Area Health Service Treatment for multiple sclerosis
GB2434578A (en) * 2006-01-26 2007-08-01 Univ Basel Transgenic animals

Also Published As

Publication number Publication date
CO6341640A2 (es) 2011-11-21
UY32038A (es) 2010-03-26
MA32621B1 (fr) 2011-09-01
CN102177179A (zh) 2011-09-07
AU2009279471A1 (en) 2010-02-11
TW201018482A (en) 2010-05-16
EP2318442A1 (en) 2011-05-11
CR20110118A (es) 2011-07-28
NZ590994A (en) 2012-09-28
IL211034A0 (en) 2011-04-28
CL2011000269A1 (es) 2012-07-20
MX2011001477A (es) 2011-03-25
US20100040616A1 (en) 2010-02-18
JP2011530533A (ja) 2011-12-22
AR072985A1 (es) 2010-10-06
KR20110044777A (ko) 2011-04-29
US20110287000A1 (en) 2011-11-24
CA2733432A1 (en) 2010-02-11
EA201100150A1 (ru) 2011-10-31
BRPI0916945A2 (pt) 2015-11-24
PE20110382A1 (es) 2011-06-27
WO2010017468A1 (en) 2010-02-11
ZA201100974B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
DOP2011000041A (es) Tratamiento de enfermedad autoinmunitaria e inflamatoria
CR20120490A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
AU2007257423A8 (en) Purine analogs
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
AR043616A1 (es) Anticuerpos contra receptor humano il-21 y usos de los mismos
Haider et al. Decreased hippocampal 5-HT and DA levels following sub-chronic exposure to noise stress: impairment in both spatial and recognition memory in male rats
CO6592067A2 (es) Proteinas de elance a cd 127
EA200901621A1 (ru) Индукция толерогенного фенотипа у зрелых дендритных клеток
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
ECSP088613A (es) Moléculas de anticuerpo que tienen especificidad para la il-6 humana
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
NI201100040A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos.
EA201000006A1 (ru) Способы и композиции для лечения аллергических заболеваний
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CO6440529A2 (es) Pirimidinonas como inhibidores de pi3k
EA201290988A1 (ru) Стереоселективный синтез фосфорсодержащих активных соединений
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CO7240399A2 (es) Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos
ECSP088751A (es) Anticuerpos contra la il-22 humana y usos para los mismos
BRPI0511111A (pt) compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários
AR064501A1 (es) Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos
ATE473735T1 (de) Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut